Jacobs Levy Equity Management Inc. Sells 27,608 Shares of Generation Bio Co. (NASDAQ:GBIO)

Jacobs Levy Equity Management Inc. lowered its stake in shares of Generation Bio Co. (NASDAQ:GBIO) by 9.2% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 273,445 shares of the company’s stock after selling 27,608 shares during the quarter. Jacobs Levy Equity Management Inc. owned 0.41% of Generation Bio worth $675,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of GBIO. Baker BROS. Advisors LP boosted its stake in Generation Bio by 61.1% during the third quarter. Baker BROS. Advisors LP now owns 1,944,945 shares of the company’s stock worth $4,804,000 after buying an additional 737,988 shares during the period. Acadian Asset Management LLC boosted its stake in shares of Generation Bio by 23.9% during the 2nd quarter. Acadian Asset Management LLC now owns 594,569 shares of the company’s stock worth $1,675,000 after purchasing an additional 114,734 shares during the period. Cubist Systematic Strategies LLC grew its holdings in Generation Bio by 91.0% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 19,046 shares of the company’s stock valued at $54,000 after purchasing an additional 9,075 shares during the last quarter. Vanguard Group Inc. raised its position in Generation Bio by 0.7% in the 1st quarter. Vanguard Group Inc. now owns 2,570,456 shares of the company’s stock worth $10,462,000 after purchasing an additional 18,205 shares during the period. Finally, Bank of New York Mellon Corp raised its position in Generation Bio by 31.2% in the 2nd quarter. Bank of New York Mellon Corp now owns 186,756 shares of the company’s stock worth $527,000 after purchasing an additional 44,378 shares during the period. Hedge funds and other institutional investors own 95.22% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the company. Needham & Company LLC reaffirmed a “buy” rating and set a $10.00 target price on shares of Generation Bio in a research note on Wednesday, October 23rd. Wedbush restated an “outperform” rating and set a $5.00 price objective on shares of Generation Bio in a report on Thursday, November 7th.

Generation Bio Stock Down 2.3 %

GBIO opened at $1.27 on Tuesday. Generation Bio Co. has a 52 week low of $1.24 and a 52 week high of $4.65. The company has a market capitalization of $84.83 million, a P/E ratio of -0.58 and a beta of 2.66. The stock’s fifty day moving average is $1.97 and its two-hundred day moving average is $2.47.

Generation Bio Profile

Generation Bio Co develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems.